Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1723 : JHOC-8  update : 2024/08/15
CommentHuman cell line derived from ovarian clear cell adenocarcinoma. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.ISHIKAWA Hiroshi (Cell Bank)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 2001
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Tissue ovary
Disease name clear cell carcinoma
Classification cancer
Year of origin 1999
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4642
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM/HamF12 + 10% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 0
User's Publication 10


To topTop
Reference

To topTop
User's Publication
14932  Ota Y, Koizume S, Nakamura Y, Yoshihara M, Takahashi T, Sato S, Myoba S, Ohtake N, Kato H, Yokose T, Miyagi E, Miyagi Y.  Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix  Oncol Rep  2021  45(3):1023-1032  PubMed ID: 33650653   DOI: 10.3892/or.2021.7944
9659  Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich  Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models  Mol Cancer Ther   2017  16(5):850-860  PubMed ID: 28292935   DOI: 10.1158/1535-7163.MCT-16-0678
7404  Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.  Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.  Mol. Carcinog.  2016  55:832-41  PubMed ID: 25856562   DOI: 10.1002/mc.22325
7410  Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.  Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.  Int. J. Oncol.  2015  46:2389-98  PubMed ID: 25846456   DOI: 10.3892/ijo.2015.2951
9634  Kanako Shinjo, Yoriko Yamashita, Eiko Yamamoto, Shinya Akatsuka, Nozomi Uno, Akihiro Kamiya, Kaoru Niimi, Yuka Sakaguchi, Tetsuro Nagasaka, Takashi Takahashi, Kiyosumi Shibata, Hiroaki Kajiyama, Fumitaka Kikkawa, Shinya Toyokuni  Expression of Chromobox Homolog 7 (CBX7) Is Associated With Poor Prognosis in Ovarian Clear Cell Adenocarcinoma via TRAIL-induced Apoptotic Pathway Regulation  Int J Cancer  2014  135(2):308-18  PubMed ID: 24375438   DOI: 10.1002/ijc.28692
9635  Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni  Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates With Worsened Prognosis  PLoS One  2013  8(3):e57724  PubMed ID: 23469222   DOI: 10.1371/journal.pone.0057724
9669  Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa  Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells  Int J Oncol  2013  43(1):63-71  PubMed ID: 23670532   DOI: 10.3892/ijo.2013.1935
9657  Nozomu Yanaihara, Michael S Anglesio, Kazunori Ochiai, Yukihiro Hirata, Misato Saito, Chie Nagata, Yasushi Iida, Satoshi Takakura, Kyosuke Yamada, Tadao Tanaka, Aikou Okamoto  Cytokine Gene Expression Signature in Ovarian Clear Cell Carcinoma  Int J Oncol   2012  41(3):1094-100  PubMed ID: 22751940   DOI: 10.3892/ijo.2012.1533
6298  Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T.  Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.  Int J Oncol  2008  32(6):1227-35  PubMed ID: 18497984   DOI: 10.3892/ijo_32_6_1227
15560  Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.  Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.  Cancer Sci  2008  99:2365-72  PubMed ID: 19032364   DOI: 10.1111/j.1349-7006.2008.00988.x



Back Back Return Top Page